United States: FDA Cracking Down On Unapproved HCT/Ps With Fourth Untitled Letter Of 2023 - Sheppard Mullin Richter & Hampton

Mondaq

07 Jun 2023 0 shares 1 views

United States: FDA Cracking Down On Unapproved HCT/Ps With Fourth Untitled Letter Of 2023 - Sheppard Mullin Richter & Hampton

Mondaq

Published 07 Jun 2023

On May 22, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) issued an untitled letter to AT Venture Center for Global Techtrepeneurship...

Full Article

United States: State Attorneys General Pen Letter To OCR Advocating For Greater Privacy Protection Of Reproductive Health Care Information - Sheppard Mullin Richter & Hampton

Mondaq 30 Jun 2023

On June 16, 2023, nearly half of the State Attorneys General[1] penned a letter (the "Letter") to the U.S. Department of Health and..

United States: Access To Abortion Pill On The Precipice: A Deep Dive Into The Federal Court Rulings That Will Decide The Fate Of Mifepristone - Sheppard Mullin Richter & Hampton
Mondaq 20 Jun 2023
United States: FDA Issues First Untitled Letter Of The Year To Xeris Pharmaceuticals - Sheppard Mullin Richter & Hampton
Mondaq 19 Jun 2023

United States: FDA Cracking Down On Unapproved HCT/Ps With Fourth Untitled Letter Of 2023 - Sheppard Mullin Richter & Hampton

United States: FDA Cracking Down On Unapproved HCT/Ps With Fourth Untitled Letter Of 2023 - Sheppard Mullin Richter & Hampton

You might like

Related news coverage

United States: State Attorneys General Pen Letter To OCR Advocating For Greater Privacy Protection Of Reproductive Health Care Information - Sheppard Mullin Richter & Hampton

Advertisement